Actively Recruiting
Phase 1 Study of SIM0613 Given by IV Infusion in Adults with Advanced or Metastatic Solid Tumors Evaluating Safety, Tolerability, and Early Treatment Effects
Led by Jiangsu Simcere Pharmaceutical Co., Ltd. · Updated on 2026-06-01
294
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating SIM0613, a new drug administered by intravenous infusion, in participants with locally advanced or metastatic solid tumors. This open-label, first-in-human Phase 1 study aims to assess the safety, tolerability, effectiveness, and how the drug moves and acts in the body. The trial includes people who have progressed on or cannot tolerate standard therapies or for whom the trial drug is considered standard treatment. The study is divided into two parts Part 1 involves dose escalation to find the appropriate dosing, followed by Part 2 which expands dosing to different solid tumor types. Treatment consists of cycles of intravenous infusions of SIM0613. Tumor tissue samples are collected at screening or prior to consent for biomarker analysis, with specific requirements depending on the study part. Participants will undergo regular safety and response monitoring for up to two years, including assessments of dose-limiting toxicity within the first 21 days and objective tumor response rate over two years. Organ function tests, pregnancy testing for women of childbearing potential, and tumor measurements per RECIST criteria will be conducted. Safety follow-up and long-term observation are included to gather detailed information on the drugs effects and tolerability.
CONDITIONS
Brief Title
SIM0613 in Participants With Advanced Solid Tumors
Research Team
Q
Qiuping Huang, Master
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here